Insys -18% following subpoena news

Insys Therapeutics (INSY) -18.4% premarket following news it received a subpoena from the Department of Health and Human Services in connection with an investigation of potential violations involving HHS programs.

The subpoena requests documents regarding Subsys, including INSY's sales and marketing practices related to the product; Subsys, a sublingual spray to treat pain in opioid-tolerate cancer patients, is one of its INSY's two marketed products.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs